BioLineRx (NASDAQ:BLRX) Stock Price Passes Above 200-Day Moving Average – Should You Sell?
by Michael Walen · The Markets DailyBioLineRx Ltd. (NASDAQ:BLRX – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.87 and traded as high as $3.32. BioLineRx shares last traded at $3.16, with a volume of 7,860 shares traded.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of BioLineRx in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has a consensus rating of “Sell”.
Get Our Latest Research Report on BioLineRx
BioLineRx Stock Performance
The company has a debt-to-equity ratio of 0.16, a current ratio of 1.58 and a quick ratio of 1.43. The stock’s 50-day moving average is $2.93 and its two-hundred day moving average is $2.87. The company has a market cap of $13.81 million, a P/E ratio of -1.65 and a beta of 1.53.
BioLineRx (NASDAQ:BLRX – Get Free Report) last posted its earnings results on Wednesday, May 27th. The biotechnology company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($1.04) by $0.68. The business had revenue of $0.48 million during the quarter, compared to the consensus estimate of $0.34 million. BioLineRx had a negative net margin of 563.70% and a negative return on equity of 37.73%.
BioLineRx Company Profile
BioLineRx (NASDAQ: BLRX) is a clinical-stage biopharmaceutical company that discovers and develops novel small-molecule therapies to address unmet medical needs. The company focuses on identifying promising drug candidates through licensing and collaboration agreements with academic institutions and biotech innovators, then advancing these candidates through preclinical and clinical development stages. BioLineRx’s pipeline spans oncology, immunology and inflammatory diseases, central nervous system disorders and pain management.
Among its clinical programs, BioLineRx is advancing targeted cancer therapies designed to improve outcomes for patients with difficult-to-treat tumors.